Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246848 | 0.94 | THRB (0.45) | THRBPOLBHTR2ADRD3HTR1A | |
| SCHEMBL6247190 | 0.92 | THRB (0.40) | CCR1THRBPOLBDRD3SIGMAR1 | |
| SCHEMBL6248103 | 0.92 | THRB (0.42) | CCR1THRBPOLBPRKAA2HTR2A | |
| SCHEMBL6249192 | 0.89 | HTR2A (0.45) | THRBPOLBPRKAA2HTR2ADRD3 | |
| SCHEMBL6250156 | 0.86 | THRB (0.43) | THRBPOLBHTR2ADRD3HTR1A | |
| SCHEMBL6245347 | 0.85 | THRB (0.44) | THRBPOLBHTR2ADRD3TP53 | |
| SCHEMBL6246775 | 0.85 | CCR1 (0.59) | CCR1TP53LMNATSHR | |
| SCHEMBL6248199 | 0.84 | THRB (0.40) | THRBPOLBDRD3TP53LMNA | |
| SCHEMBL6247894 | 0.82 | THRB (0.40) | THRBPOLBHTR2AHTR2CSIGMAR1 | |
| SCHEMBL6246930 | 0.81 | HTR2A (0.44) | THRBPOLBPRKAA2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | claimed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | claimed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | CCR1 4/4885THRB 2895/4885POLB 4429/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | CCR1 1/4885THRB 3608/4885POLB 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.